β-phenylethylidenehydrazine, a novel inhibitor of GABA transaminase

Drug Development Research

Volumn 54, Issue 1, 2001, Pages 35-39

  Paslawski, T ^a,b   Knaus, E ^a,b   Iqbal, N ^a,b   Coutts, R T ^a,b   Baker, G B ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

aminobutyric acid (GABA); GABA transaminase; Monoamine oxidase; Phenylethylidenehydrazine

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; ANTIDEPRESSANT AGENT; ANTIPANIC AGENT; BETA PHENYLETHYLIDENEHYDRAZINE; DRUG METABOLITE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0035195615     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.1202     Document Type: Article

References (5)

1. Baker GB, Wong JFT, Yeung JM, Coutts RT. 1991. Effects of the antidepressant phenelzine on brain levels of γ-aminobutyric acid (GABA). J Affect Disord 21:207-211.
2. 14C, an irreversible inhibitor of monoamine oxidase. I. Studies in vitro. Biochem Pharmacol 18:1011-1020.
3. DeAngelis A. 1992. Comparative effects of valproate, anxiolytic, or anxiogenic drugs on the light/dark aversion test. Drug Dev Res 25:331-338.
4. Green AR, Hainsworth AH, Jackson DM. 2000. GABA potentiation: a logical pharmacological approach for the treatment of acute ischemic stroke. Neuropharmacology 39:1483-1494.
5. Keck PE, McElroy SL, Tugrul KC, Bennett JA, Smith JMR. 1993a. Antiepileptic drugs for the treatment of panic disorder. Neuropsychopharmacology 27:150-153.